** U.S.-listed shares of Australia-based Mesoblast MSB.AX rise 44.2% to $17.67 premarket
** The U.S. Food and Drug Administration late on Wednesday approved co's cell therapy for treating graft-versus-host disease (GVHD)
** The therapy, branded as Ryoncil, is approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard steroid therapy
** GVHD is a complication that might occur after a cell transplant, where the donated stem cells attack the recipient's cells, mistaking them for an unfamiliar threat
** Up to last close, stock rose ~457% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。